-
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.
Thaisrivongs S,
Skulnick HI,
Turner SR,
Strohbach JW,
Tommasi RA,
Johnson PD,
Aristoff PA,
Judge TM,
Gammill RB,
Morris JK,
Romines KR,
Chrusciel RA,
Hinshaw RR,
Chong KT,
Tarpley WG,
Poppe SM,
Slade DE,
Lynn JC,
Horng MM,
Tomich PK,
Seest EP,
Dolak LA,
Howe WJ,
Howard GM,
Watenpaugh KD, et al.
Upjohn, Inc., Kalamazoo, Michigan 49001, USA.
PMID: 8893827 [PubMed - indexed for MEDLINE]
-
Cited by 6 PubMed Central articles
-
Evaluating the potency of HIV-1 protease drugs to combat resistance.
Hou T, McLaughlin WA, Wang W.
Proteins. 2008 May 15; 71(3):1163-74.
[Proteins. 2008]
-
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL.
J Virol. 2006 Nov; 80(21):10794-801. Epub 2006 Aug 23.
[J Virol. 2006]
-
HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
Perryman AL, Lin JH, McCammon JA.
Protein Sci. 2004 Apr; 13(4):1108-23.
[Protein Sci. 2004]
- » See all...
Structures reported by this article